NORWELL, Mass. — The National Organization for Rare Disorders (NORD®) has officially announced a new request for applications aimed at implementing two additional patient registries on its nationally recognized NORD® IAMRARE® platform. This significant healthcare initiative is made possible through dedicated funding provided by the Rare Disease Cures Accelerator–Data and Analytics Platform (RDCA-DAP®), a collaborative agreement established with the Critical Path Institute and funded by the U.S. Food and Drug Administration (FDA).
The announcement marks another milestone in the ongoing nationwide effort to empower rare disease communities, harness patient-reported data, and accelerate the development of critical diagnostics, treatments, and therapies for millions of Americans living with rare conditions.
The IAMRARE platform has long served as a foundational infrastructure for patient-led research, offering a standardized and secure environment where patient advocacy organizations can gather vital health information directly from individuals and families affected by rare diseases. By opening this application process, NORD aims to extend these vital technological and structural capabilities to two new rare disease communities, helping them build robust foundations for future clinical investigations.
“This opportunity builds on NORD’s work supporting rare disease nonprofits,” says Tracey Sikora, Vice President of Research and Clinical Programs at NORD. Highphasizing the tangible impact of these community-driven registries, Sikora noted that research studies led directly by rare disease communities represent an indispensable source of medical data. Insights derived from IAMRARE-hosted studies have historically contributed to meaningful advancements across the medical field, including the development of clinical outcome assessments, updates to professional treatment guidelines, and at least one official FDA approval.
Collaboration and Comprehensive Support for Selected Communities
Under the terms of the new initiative, successful applicants will collaborate closely with NORD beginning in April 2027 to design, build, and officially launch a customized patient registry tailored to their specific rare disease community.
NORD’s involvement extends far beyond simple software hosting. The organization will build and host the registry website while providing comprehensive training and ongoing guidance to the registry sponsors. This hands-on support guides organizations through every critical phase of registry development, including establishing a dedicated registry advisory board, developing a rigorous study protocol, building and customizing patient surveys, navigating the complex Institutional Review Board (IRB) process, and determining transparent criteria for sharing the collected data with qualified researchers.
The initiative addresses a long-standing challenge in the rare disease space: the fragmentation of medical data. By centralizing patient-reported data through structured platforms like IAMRARE, rare disease organizations can transform anecdotal experiences into robust, quantifiable evidence that captures the natural history of a condition, measures patient quality of life, and provides researchers with the high-quality datasets required to attract pharmaceutical investment and clinical trial interest.
Application Criteria, Important Deadlines, and Next Steps
The formal request for applications is officially open and will accept submissions through January 10, 2027. Organizations that submit successful applications will be notified by February 1, 2027, with official registry implementation activities scheduled to commence in April 2027. Interested rare disease advocacy groups and nonprofit leaders can access the application portal online.
Organizations seeking further clarification or having specific inquiries regarding the application criteria and submission process are encouraged to reach out to NORD program administrators directly via email.
About the NORD® IAMRARE® Platform
The NORD® IAMRARE Platform currently hosts more than 50 live, active registries sponsored directly by patient advocacy organizations. Designed specifically for the collection of secure, standardized, and patient-reported data, the platform allows communities to take the lead in natural history studies and post-market surveillance. Additional information regarding the platform and its capabilities can be found by visiting the official website at iamrare.org.
About the Rare Disease Cures Accelerator–Data and Analytics Platform (RDCA-DAP®)
The Rare Disease Cures Accelerator–Data and Analytics Platform (RDCA-DAP) is an innovative, FDA-sponsored initiative designed to provide a centralized and standardized infrastructure. By aggregating existing data and supporting new data generation, RDCA-DAP aims to comprehensively characterize rare diseases and ultimately accelerate the pace of therapy development across the entire medical landscape. Detailed information regarding the initiative is available through the Critical Path Institute at c-path.org/programs/rdca-dap.
About the National Organization for Rare Disorders (NORD®)
Founded in 1983, the National Organization for Rare Disorders (NORD®) is a prominent, independent, and nonpartisan nonprofit organization dedicated to identifying, treating, and curing rare disorders through programs of education, advocacy, research, and patient services. NORD fights on behalf of the more than 30 million Americans living with rare diseases, a population frequently underserved by traditional medical research pathways.
Operating in close partnership with more than 350 disease-specific member patient organizations, NORD also collaborates extensively with 49 designated NORD Rare Disease Centers of Excellence. These centers span over 170 academic medical centers, specialized research institutions, and major children’s hospitals nationwide, working collectively to advance specialized clinical care, scientific research, and professional education. Through these strategic networks, NORD continues to build a more hopeful and inclusive future for individuals and families impacted by rare diseases. More information about NORD and its nationwide initiatives can be found at rarediseases.org.
Media Contact:
Cheryl Herbert
Vice President, Marketing & Communications
National Organization for Rare Disorders (NORD)
Email: [email protected]
